Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Clinical Nuclear Medicine|August 18, 2012
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancerCharline Lasnon, Rodney J Hicks, Jean-Mathieu Beauregard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01Jean Louis Pujol, Jean Luc Breton, Radj Gervais, et al.
Journal of Cancer Research and Therapeutics|December 13, 2022
Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 studyNicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancerRodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.
Future Oncology (London, England)|June 22, 2021
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50Renaud Descourt, Christos Chouaid, Maurice Pérol, et al.
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Journal for Immunotherapy of Cancer|January 29, 2020
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitorsCharles Dolladille, Stephane Ederhy, Stéphane Allouche, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2015
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01Pierre Fournel, Alain Vergnenégre, Gilles Robinet, et al.
Pageof 9